In addition, increasing pediatric data is emerging for BRAF and MEK inhibitors in the treatment of surgically inaccessible gliomas that express BRAF V600E mutations, with an acceptable side effect profile in this age group [1, 3, 4, 16, 18, 29]. Here, BRAF is linked to central nervous system cancer.